A Phase I Trial of Vemurafenib in Combination With Cetuximab and Irinotecan in Patients With BRAF V600 Mutant Advanced Solid Malignancies
Latest Information Update: 22 Mar 2024
At a glance
- Drugs Vemurafenib (Primary) ; Cetuximab; Irinotecan
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions
- 18 Mar 2024 Planned End Date changed from 31 Mar 2024 to 31 Mar 2026.
- 18 Mar 2024 Planned primary completion date changed from 31 Mar 2024 to 31 Mar 2026.
- 24 May 2019 Planned number of patients changed from 35 to 33.